{ }
001122334455554433221100
001122334455554433221100

novo nordisk partners with ascendis to develop long acting glp 1 drugs

Novo Nordisk has partnered with Ascendis Pharma to develop a long-acting GLP-1 drug and other metabolic treatments, potentially paying up to $285 million based on progress. Ascendis will receive additional fees for each drug developed, leveraging its delivery technology to reduce dosing frequency. The collaboration aims to enhance patient adherence to medications for obesity and diabetes, addressing high discontinuation rates in current treatments.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.